INC Research (INCR) Names Michael Gibertini COO and Tara Fitzgerald President/Clinical Development
- Wall Street falls as investors ready for Trump's inauguration
- IBM (IBM) Tops Q4 EPS by 13c, FY17 EPS Guidance Beats Consensus
- American Express (AXP) Misses Q4 EPS by 7c, FY17 EPS Guidance Tops Views at Mid-Poinit
- Skyworks Solutions (SWKS) Tops Q1 EPS by 3c, Offers Q2 Guidance, Announces Buyback
- After-Hours Stock Movers 01/19: (SWKS) (QRVO) (NVAX) Higher; (AFMD) (SGYP) (IBM) Lower (more...)
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
INC Research Holdings, Inc. (Nasdaq: INCR) announced the promotions of Michael Gibertini, PhD, and Tara Fitzgerald to key executive leadership roles within the Company. Dr. Gibertini, who currently serves as INC Research’s President, Clinical Development, has been promoted to Chief Operating Officer (COO) succeeding Alistair Macdonald while Tara Fitzgerald, Executive Vice President, Biometrics, has been appointed President, Clinical Development Services. The appointments of Dr. Gibertini and Ms. Fitzgerald are being made in conjunction with the Company’s CEO succession plan previously announced on July 28, 2016, with COO Alistair Macdonald assuming the role of Chief Executive Officer and joining the Board of Directors for INC Research effective Oct. 1, 2016. Alistair Macdonald succeeds Jamie Macdonald, who also has stepped down from the Board and will serve through Feb. 29, 2017, as Vice Chairman, reporting to the Chairman of the Board to assist with the transition.
"Michael and Tara both bring experienced leadership, extensive industry and in-depth organizational knowledge and a strategic vision to help guide the future growth and success of INC Research," said Chief Executive Officer Alistair Macdonald. "As President, Clinical Development, Michael has continued to grow and build on INC’s therapeutic expertise as a key differentiator while enhancing our scientific focus to deliver truly innovative clinical development solutions for customers. Tara is a proven leader who has delivered exceptional results during her tenure with INC, guiding our Biometrics business to deliver consistently strong performance while also providing senior-level leadership for numerous other business-critical initiatives. We look forward to her continued leadership in further optimizing our overall delivery while driving growth across our key value chains.”
Alistair Macdonald concluded, “I am thrilled to assume the role of CEO of INC Research at this exciting time in our growth. With our 2016-2018 business strategy well underway, our direction is clear and we remain focused on our mission of helping biopharmaceutical customers worldwide bring new medicines to market for patients in need. I'm delighted to have Michael and Tara as part of our leadership team to help guide the next phase of INC Research’s growth as we continue on our journey to becoming CRO of Choice.”
As COO, Dr. Gibertini has global responsibility for all operational aspects of INC Research, including Clinical Operations and Clinical Development services. He joined INC Research in 2005 and prior to being appointed President, Clinical Development in 2015 served as President and General Manager, Central Nervous (CNS). Dr. Gibertini's experience includes more than 30 years in the pharmaceutical, CRO, academic and private and hospital practice settings and he is a well-known expert and leader in CNS clinical trials methodology. In 2015 Dr. Gibertini was named to the annual PharmaVOICE 100 list of the most inspiring people in the life sciences industry. Dr. Gibertini will report directly to CEO Alistair Macdonald.
As President, Clinical Development Services, Tara Fitzgerald will provide global leadership for delivery of the Company’s Clinical Support Services, including Study Start-Up, Biometrics and Safety and Pharmacovigilance offerings across Phase I to IV clinical trials as well the continued growth and expansion of its key value chains, including Late Phase, Consulting, Medical Devices and Functional Service Provision (FSP). Ms. Fitzgerald joined INC Research in May 2011 and has served as Executive Vice President, Biometrics since April 2013, providing global leadership for the Company’s Data Operations, Biostatistics, Medical Writing, Safety and Pharmacovigilance and Biometrics Project Management offerings. Her experience includes more than 20 years in senior leadership roles within the Biometrics field. Ms. Fitzgerald was named to the annual PharmaVOICE 100 list of the most inspiring people in the life sciences industry in 2014. She will report directly to Dr. Gibertini.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sonic Corp (SONC) Elects Steven Davis to Board of Directors
- Flagstar Bancorp (FBC) Names Jennifer Whip to Board of Directors
- Wells Fargo (WFC) Says International Group to be Integrated into Other Wholesale Banking Business Lines
Create E-mail Alert Related CategoriesCorporate News, Management Changes, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!